March 28, 2018
Tokyo-based startup Curadim Pharma has grabbed worldwide rights to develop, manufacture, and market Ube Industries’ lysophosphatidic acid receptor 1 (LPA1) selective antagonist CP2090, the two companies said on March 27. CP2090 is expected to selectively bind and inhibit LPA1, thereby...read more